Kazia Therapeutics LTD

Kazia Therapeutics reports a board-approved award of 100,000 stock options to Director Steven R. S. Coffey.

Kazia Therapeutics reports on the grant of stock options and restricted share units to its CEO, John E. Friend II, with vesting schedules extending over several years.

Kazia Therapeutics reports the grant of 150,000 stock options to VP, Finance and Controller Jeffrey Bonacorda, with specific vesting and exercise terms.

Kazia Therapeutics reports a director, Ebru Davidson, was granted 100,000 stock options with an exercise price of $9.10 per ADS, vesting in January 2027.

Kazia Therapeutics reports a grant of 100,000 stock options to Director, CMC David Cain, with an exercise price of $9.10 per ADS.

Kazia Therapeutics reports a board-approved award of 75,000 stock options to Director Robert F. Apple.

Ikarian Capital, LLC and Neil Shahrestani have jointly reported a beneficial ownership of 4.9% in Kazia Therapeutics Limited's American Depositary Shares.

Jorey Chernett has filed a Schedule 13G, reporting beneficial ownership of 2,114,649 American Depositary Shares in Kazia Therapeutics Ltd, representing 18.5% of the class.

Jorey Chernett has reported an increased beneficial ownership of 13.90% in Kazia Therapeutics Ltd, holding 1,588,129 American Depositary Shares.

Alumni Capital LP and its affiliates have filed an exit statement, reporting zero beneficial ownership in Kazia Therapeutics Ltd. American Depository Shares.

Dauntless Investment Group, LLC filed an amended Schedule 13G, reporting a 0.0% passive ownership stake in Kazia Therapeutics LTD.

Lynwood Capital Management Inc., Ben Shapiro, and Lynwood Opportunities Master Fund have jointly reported a 5.4% beneficial ownership stake in Kazia Therapeutics Limited.